Big Rock Partners Acquisition Corp. (BRPA)
39.52 +3.48 (9.66%)
After hours: 5:57PM EST
Chart Events
Performance Outlook
| Previous Close | 35.76 |
| Open | 35.00 |
| Bid | 35.91 x 800 |
| Ask | 43.48 x 3200 |
| Day's Range | 33.34 - 37.34 |
| 52 Week Range | 9.80 - 76.99 |
| Volume | 134,776 |
| Avg. Volume | 94,274 |
| Market Cap | 96.884M |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, BRPA, and ZAGG Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
- PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, FIII, JWS and BRPA Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
- PR Newswire
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing multiple drugs for the treatment of patients with Critical COVID-19 who are hospitalized or in intensive care units. ZYESAMI™ will be included as one of the first drugs targeting Respiratory Failure in critically ill COVID-19 patients.
